Th2-inducing adjuvant treatment for osteolysis
Active immunization and a formulation for treating or preventing osteolysis caused by Wear Particles, comprising: a) a Th2 -inducing adjuvant, and b) Wear Particles.
1 . A method of preventing or treating osteolysis comprising the steps of:
a) administering to a patient a formulation comprising:
i) a Th2-inducing adjuvant, and
ii) Wear Particles.
2 . The method of claim 1 wherein the formulation is injected into the patient.
3 . The method of claim 1 wherein the formulation is implanted into the patient through an incision.
4 . The method of claim 3 wherein an orthopedic implant capable of producing Wear Particles is implanted into the patient through the incision.
5 . The method of claim 4 wherein the formulation is attached to the implant during implantation of the implant.
6 . The method of claim 1 wherein an orthopedic implant capable of producing Wear Particles is implanted into the patient prior to the administration.
7 . The method of claim 1 wherein an orthopedic implant capable of producing Wear Particles is implanted into the patient after the administration.
8 . The method of claim 1 wherein the adjuvant comprises a metallic hydroxide component.
9 . The method of claim 8 wherein the adjuvant is alum.
10 . The method of claim 1 wherein the formulation further comprises iii) collagen.
11 . A formulation for treating or preventing osteolysis caused by Wear Particles, comprising:
i) a Th2-inducing adjuvant, and
ii) Wear Particles.
12 . The formulation of claim 11 wherein the adjuvant comprises a metallic hydroxide.
13 . The formulation of claim 11 wherein the formulation further comprises iii) collagen.
14 . The formulation of claim 11 provided in the form of a gel.
15 . The formulation of claim 11 wherein the Wear Particles have a D 50 particle size of less than 10 microns.
16 . The formulation of claim 11 wherein the Wear Particles comprises a polymer.
17 . The formulation of claim 16 wherein the polymer is polyethylene.
18 . The formulation of claim 11 wherein the Wear Particles comprise titanium.
19 . The formulation of claim 11 wherein the Wear Particles comprise cobalt-chrome.
20 . The formulation of claim 11 wherein the Wear Particles comprises PMMA.
21 . A kit comprising:
a) a formulation adapted to elicit a Th2 immune response, and
b) an orthopedic implant having an articulation interface.
22 . The kit of claim 21 wherein the orthopedic implant is a hip joint prosthesis.
23 . The kit of claim 22 wherein the orthopedic implant is an acetabular cup.
24 . The kit of claim 23 wherein the acetabular cup is a UHMWPE liner.
25 . The kit of claim 21 wherein the orthopedic implant is a knee joint prosthesis.
26 . The kit of claim 22 wherein the knee joint prothesis is a tibial component.
27 . The kit of claim 23 wherein the tibial component is a UHMWPE insert.
28 . The kit of claim 21 wherein the formulation comprises:
i) a Th2-inducing adjuvant, and
ii) Wear Particles.
29 . The kit of claim 28 wherein the adjuvant comprises a metallic hydroxide.
30 . The kit of claim 28 wherein the adjuvant comprises alum.
31 . The kit of claim 28 wherein the formulation is provided in the form of a gel.
32 . The kit of claim 28 wherein the Wear Particles comprises a polymer.
33 . The kit of claim 28 wherein the polymer is polyethylene.
34 . The kit of claim 28 wherein the Wear Particles comprise titanium.
35 . The kit of claim 28 wherein the Wear Particles comprise cobalt-chrome.
36 . An orthopedic implant having surface having a coating thereon, wherein the coating is adapted to elicit a Th2 immune response.
37 . The implant of claim 36 wherein the coating comprises a metallic cation.
38 . The implant of claim 37 wherein the coating comprises alum.
39 . The implant of claim 36 wherein the coating is provided in the form of a gel.
40 . The implant of claim 36 wherein the surface having the coating is an outer surface.
41 . The implant of claim 36 wherein the surface having the coating is an inner surface.
42 . A formulation for treating or preventing osteolysis caused by Wear Particles, comprising:
a) a Th2-inducing adjuvant, and
b) particles selected from the group consisting of a polymer, titanium, titanium alloy, cobalt chrome, and PMMA, and mixtures thereof.
43 . The formulation of claim 42 further comprising:
c) collagen.
44 . The formulation of claim 43 wherein the collagen comprises type II collagen.
45 . The formulation of claim 43 wherein the collagen comprises fibrillar collagen.
46 . The formulation of claim 43 wherein the formulation further comprises d) a therapeutic protein.
47 . The formulation of claim 42 wherein the particles comprise a mixture of polymer and titanium alloy particles.
48 . A formulation for treating or preventing osteolysis caused by Wear Particles, comprising:
a) a Th2-inducing adjuvant, and
b) particles having a D50 particle size of between 0.1 um and 10 um.
49 . A method of preventing or treating sciatica from a nucleus pulposus of a patient, comprising the steps of:
a) administering to the patient a formulation comprising:
i) a Th2-inducing adjuvant, and
ii) nucleus pulposus.